Evidence map›Paper›PMID 27583544›Full record

ArticlePloS one2016

Influence of Statins on Survival Outcome in Patients with Metastatic Castration Resistant Prostate Cancer Treated with Abiraterone Acetate.

Martin Boegemann, Katrin Schlack, Ann-Kathrin Fischer, Joachim Gerß, Julie Steinestel, Axel Semjonow, Andres Jan Schrader, Laura-Maria Krabbe

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 5 pooled it
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 5 syntheses or guidelines pooled it, 21 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Article
  7. Targeting lipid metabolism in metastatic prostate cancer.Therapeutic advances in medical oncology · 2023
    Review
  8. Article
  9. Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Martin BoegemannDepartment of Urology, Muenster University Medical Center, Muenster, Germany.
Katrin SchlackDepartment of Urology, Muenster University Medical Center, Muenster, Germany.
Ann-Kathrin FischerDepartment of Urology, Muenster University Medical Center, Muenster, Germany.
Joachim GerßInstitute of Biostatistics and Clinical Research of the Westfalian Wilhelms-University Muenster, Schmeddingstraße 56, D-48149 Muenster, Germany.
Julie SteinestelDepartment of Urology, Muenster University Medical Center, Muenster, Germany.
Axel SemjonowDepartment of Urology, Muenster University Medical Center, Muenster, Germany.
Andres Jan SchraderDepartment of Urology, Muenster University Medical Center, Muenster, Germany.
Laura-Maria KrabbeDepartment of Urology, Muenster University Medical Center, Muenster, Germany.
The University of Texas Southwestern Medical Center · USUniversity of Münster · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveEven though the exact mechanism is largely unknown until now, statins are supposed to improve survival outcomes in various malignancies. For prostate cancer however, statins are known to compete with dehydroepiandrosterone (DHEAS) for the transport into the cytosol both using the cell by the Solute Carrier Transporter and thus diminish the cellular uptake of DHEAS as a precursor of androgens. Abiraterone inhibits CYP17A1 and thus effectively decreases the production of all relevant androgens including DHEAS. In this study we examined whether statins still affect survival outcome in patients with metastatic castration resistant prostate cancer (mCRPC) when treated with Abiraterone. PATIENTS AND

methods108 men with mCRPC treated with Abiraterone from 02/2010 to 07/2015 with (n = 21) or without (n = 87) concomitant treatment with statins were investigated. Progression free survival (PFS) and overall survival (OS) were analyzed using Kaplan-Meier-estimates and univariate Cox-regression analysis. The influence on best clinical benefit under Abiraterone treatment was analyzed with bivariate and multivariate logistic regression analysis.

resultsPSA-decline ≥ 50% was not significantly different in both groups (57 vs. 53%; p = 0.73). The median PFS (9 vs. 10 months; p = 0.97) and OS (14 vs. 18 months; p = 0.77) did not differ significantly between those men treated with and without concomitant statin therapy, respectively. Accordingly, there was no improvement for best clinical benefit in patients using statins (odds ratio: 1.2 (CI: 0.4-4.2); p = 0.76).

conclusionUse of statins as concomitant medication did not improve survival outcomes or best clinical benefit in men with mCRPC treated with Abiraterone.

Indexed as

Abiraterone AcetateAgedCohort StudiesHumansHydroxymethylglutaryl-CoA Reductase InhibitorsMaleMiddle AgedNeoplasm MetastasisProstatic Neoplasms, Castration-ResistantSurvival AnalysisAbiraterone AcetateHydroxymethylglutaryl-CoA Reductase Inhibitors

Identifiers

PMID27583544
PMCPMC5008748
OpenAlexW2512364469

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.